Cargando…

Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump

Treatment with continuous s.c. insulin infusion (CSII) provides better glycemic control and lower risk of hypoglycemia than conventional therapy with multiple daily insulin injections. These benefits have been related to a more reliable absorption and an improved pharmacokinetic profile of insulin d...

Descripción completa

Detalles Bibliográficos
Autores principales: Boronat, Mauro, Sánchez-Hernández, Rosa M, Rodríguez-Cordero, Julia, Jiménez-Ortega, Angelines, Nóvoa, Francisco J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285755/
https://www.ncbi.nlm.nih.gov/pubmed/25614824
http://dx.doi.org/10.1530/EDM-14-0081
_version_ 1782351594021453824
author Boronat, Mauro
Sánchez-Hernández, Rosa M
Rodríguez-Cordero, Julia
Jiménez-Ortega, Angelines
Nóvoa, Francisco J
author_facet Boronat, Mauro
Sánchez-Hernández, Rosa M
Rodríguez-Cordero, Julia
Jiménez-Ortega, Angelines
Nóvoa, Francisco J
author_sort Boronat, Mauro
collection PubMed
description Treatment with continuous s.c. insulin infusion (CSII) provides better glycemic control and lower risk of hypoglycemia than conventional therapy with multiple daily insulin injections. These benefits have been related to a more reliable absorption and an improved pharmacokinetic profile of insulin delivered through CSII therapy. However, even for patients treated with CSII, exaggerated postmeal hyperglycemic excursions and late postabsorptive hypoglycemia can still constitute a therapeutic challenge. Two female patients with type 1 diabetes who began treatment with CSII required to increase their previous breakfast insulin-to-carbohydrate ratio in order to achieve postprandial glycemic goals. However, they simultaneously presented recurrent episodes of late hypoglycemia several hours after breakfast bolus. Advancing the timing of the bolus was ineffective and bothersome for patients. In both cases, the best therapeutic option was to set a basal insulin rate of zero units per hour during 6 h after breakfast. Even so, they need to routinely take a midmorning snack with 10–20 g of carbohydrates to avoid late postabsorptive hypoglycemia. They have been using this insulin schedule for about 3 years without complications. The action of prandial insulin delivered through insulin pumps can be inappropriately delayed for the requirements of some patients. Although suspension of basal rate can be an acceptable therapeutic alternative for them, these cases demonstrate that new strategies to improve the bioavailability of prandial insulin infused through CSII are still needed. LEARNING POINTS: CSII remains the most physiologically suitable system of insulin delivery available today. Additionally, the duration of action of prandial insulin delivered through insulin pumps can be excessively prolonged in some patients with type 1 diabetes. These patients can present recurrent late episodes of hypoglycemia several hours after the administration of insulin boluses. The routine suspension of basal insulin for several hours, leaving meal bolus to cover both prandial and basal insulin requirements, can be a therapeutic option for these subjects.
format Online
Article
Text
id pubmed-4285755
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-42857552015-01-22 Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump Boronat, Mauro Sánchez-Hernández, Rosa M Rodríguez-Cordero, Julia Jiménez-Ortega, Angelines Nóvoa, Francisco J Endocrinol Diabetes Metab Case Rep Unusual Effects of Medical Treatment Treatment with continuous s.c. insulin infusion (CSII) provides better glycemic control and lower risk of hypoglycemia than conventional therapy with multiple daily insulin injections. These benefits have been related to a more reliable absorption and an improved pharmacokinetic profile of insulin delivered through CSII therapy. However, even for patients treated with CSII, exaggerated postmeal hyperglycemic excursions and late postabsorptive hypoglycemia can still constitute a therapeutic challenge. Two female patients with type 1 diabetes who began treatment with CSII required to increase their previous breakfast insulin-to-carbohydrate ratio in order to achieve postprandial glycemic goals. However, they simultaneously presented recurrent episodes of late hypoglycemia several hours after breakfast bolus. Advancing the timing of the bolus was ineffective and bothersome for patients. In both cases, the best therapeutic option was to set a basal insulin rate of zero units per hour during 6 h after breakfast. Even so, they need to routinely take a midmorning snack with 10–20 g of carbohydrates to avoid late postabsorptive hypoglycemia. They have been using this insulin schedule for about 3 years without complications. The action of prandial insulin delivered through insulin pumps can be inappropriately delayed for the requirements of some patients. Although suspension of basal rate can be an acceptable therapeutic alternative for them, these cases demonstrate that new strategies to improve the bioavailability of prandial insulin infused through CSII are still needed. LEARNING POINTS: CSII remains the most physiologically suitable system of insulin delivery available today. Additionally, the duration of action of prandial insulin delivered through insulin pumps can be excessively prolonged in some patients with type 1 diabetes. These patients can present recurrent late episodes of hypoglycemia several hours after the administration of insulin boluses. The routine suspension of basal insulin for several hours, leaving meal bolus to cover both prandial and basal insulin requirements, can be a therapeutic option for these subjects. Bioscientifica Ltd 2015-01-01 2015 /pmc/articles/PMC4285755/ /pubmed/25614824 http://dx.doi.org/10.1530/EDM-14-0081 Text en © 2015 The authors This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/deed.en_GB) .
spellingShingle Unusual Effects of Medical Treatment
Boronat, Mauro
Sánchez-Hernández, Rosa M
Rodríguez-Cordero, Julia
Jiménez-Ortega, Angelines
Nóvoa, Francisco J
Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
title Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
title_full Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
title_fullStr Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
title_full_unstemmed Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
title_short Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
title_sort suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
topic Unusual Effects of Medical Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285755/
https://www.ncbi.nlm.nih.gov/pubmed/25614824
http://dx.doi.org/10.1530/EDM-14-0081
work_keys_str_mv AT boronatmauro suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump
AT sanchezhernandezrosam suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump
AT rodriguezcorderojulia suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump
AT jimenezortegaangelines suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump
AT novoafranciscoj suspensionofbasalinsulintoavoidhypoglycemiaintype1diabetestreatedwithinsulinpump